H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 19.12 CNY -5.3% Market Closed
Market Cap: 11.5B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hualan Biological Bacterin Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Gross Profit
ÂĄ2B
CAGR 3-Years
-2%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Gross Profit
ÂĄ3.3B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
22%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ11.7B
CAGR 3-Years
3%
CAGR 5-Years
26%
CAGR 10-Years
38%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
11.5B CNY
Industry
Biotechnology

Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Intrinsic Value
30.08 CNY
Undervaluation 36%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Gross Profit?
Gross Profit
2B CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Gross Profit amounts to 2B CNY.

What is Hualan Biological Bacterin Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
25%

Over the last year, the Gross Profit growth was 39%. The average annual Gross Profit growth rates for Hualan Biological Bacterin Inc have been -2% over the past three years , 25% over the past five years .

Back to Top